Sign In
Buy MBRX
$0.400
-0.620 (-60.78%)
At Close: Jul 31, 2026
Moleculin Biotech, Inc to Present at the Virtual Investor Roundtable Event
08:05am, Friday, 12'th Nov 2021
HOUSTON, Nov. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
MBRX Stock: Why It Increased Today
03:54pm, Tuesday, 19'th Oct 2021
The stock price of Moleculin Biotech Inc (NASDAQ: MBRX) increased by over 2% during intraday trading today. This is why it happened.
HOUSTON, Oct. 19, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
HOUSTON, Oct. 18, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ
Moleculin to Present at the 2021 Cantor Virtual Global Healthcare Conference
07:05am, Monday, 27'th Sep 2021
HOUSTON, Sept. 27, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
08:05am, Friday, 17'th Sep 2021
HOUSTON, Sept. 17, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting
Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update
08:18am, Thursday, 12'th Aug 2021
HOUSTON, Aug. 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
HOUSTON, July 13, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
HOUSTON, June 21, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targ
Moleculin Announces Inclusion in the Russell 2000® Index
09:05am, Tuesday, 15'th Jun 2021
HOUSTON, June 15, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates target
Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients
11:23am, Tuesday, 25'th May 2021
The FDA has signed off Phase 1b/2 trial for Moleculin Biotech Inc's (NASDAQ: MBRX) Annamycin to treat soft tissue sarcoma lung metastases. Annamycin is the company's next-generation anthracycline t
Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases
09:05am, Tuesday, 25'th May 2021
HOUSTON, May 25, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update
07:35am, Wednesday, 12'th May 2021
HOUSTON, May 12, 2021 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting h
Moleculin Biotech to Present at the Q2 Virtual Investor Summit
08:05am, Tuesday, 11'th May 2021
HOUSTON, May 11, 2021 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeti
WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate
07:30am, Tuesday, 11'th May 2021
VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to an
